EXEL News and Press, Exelixis Inc. From 05/10/22

- Total Revenues of $356.0 million, Cabozantinib Franchise Revenues of $310.3 million - - GAAP Diluted EPS of $0.21, Non-GAAP Diluted EPS of $0.26 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) today ...

- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2022 Healthcare C...

It's a popular misconception in the investing world that you need a bucketload of money to enter the stock market. In fact, long-term investors can start with just $1,000 and the right growth stocks. Growth stocks need time to show their full potential. But with a little bit of patience, ev...

– Approval is based on COSMIC-311 trial, in which CABOMETYX demonstrated significant improvement in progression-free survival versus placebo – Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European C...

European Commission (EC) approved Ipsen (OTCPK:IPSEF) (OTCPK:IPSEF) and Exelixis' (EXEL) Cabometyx as a standalone therapy for certain patients with differentiated thyroid cancer (DTC). The EC approval allows for the use of of Cabometyx (cabozantinib) to treat adult patients with lo...

The overall price growth since the inception of IDNA is quite impressive, considering the huge impact of the Covid-19 pandemic in the U.S. equity market. Huge price loss in the past 12 months, but positive price gain in the past three years, is an apparently visible trend in Genomics-...

Value investing consists of buying unappreciated or ignored stocks at attractive prices. Value investing avoids the current stock market darlings. Lakonishok created a stir in the finance community through his research in behavioral finance. For further details see: Find...

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2022 financial results will be released on Tuesday, May 10, 2022 after the markets close. At 5:00 p.m. ET / 2:00 p....

FLORHAM PARK, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Frank Karbe to its Board of Directors...

Driven by their blockbuster Cabo, Exelixis generated $1.43B in total revenues translating to a 45.3% year-over-year (YOY) increase. For further growth, the company is expanding Cabo's label in multiple ongoing Phase 3 investigations. Aside from Cabo, Exelixis is tinkering with sma...